For the quarter ended September 2026, Teva Pharmaceutical Industries Ltd. (TEVA Quick QuoteTEVA - Free Report) reported revenue of $4.4 billion, down 1.9% over the same period last year. EPS came in at $0.86, compared to $0.78 in the year-ago quarter.

The reported revenue represents a surprise of +3.61% over the Zacks Consensus Estimate of $4.24 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +19.44%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- United States- COPAXONE: $58 million compared to the $59.92 million average estimate based on three analysts. The reported number represents a change of -6.5% year over year.
• Geographic Revenue- United States- BENDEKA and TREANDA: $30 million versus $27.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.3% change.
• Geographic Revenue- United States- Other: $114 million compared to the $112.67 million average estimate based on three analysts. The reported number represents a change of +12.9% year over year.
• Geographic Revenue- Europe- AJOVY: $84 million compared to the $73.94 million average estimate based on three analysts. The reported number represents a change of +27.3% year over year.
• Geographic Revenue- Europe- Other: $111 million versus the three-analyst average estimate of $80.51 million. The reported number represents a year-over-year change of +22%.
• Geographic Revenue- International Markets- AJOVY: $48 million versus $35.72 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +60% change.
• Geographic Revenue- International Markets- Other: $105 million versus $75.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +28.1% change.
• Geographic Revenue- Europe- Generic products (including OTC and biosimilars): $1.03 billion versus the three-analyst average estimate of $1.02 billion. The reported number represents a year-over-year change of +5.2%.
• Geographic Revenue- Europe- COPAXONE: $38 million compared to the $44.33 million average estimate based on three analysts. The reported number represents a change of -13.6% year over year.
• Geographic Revenue- Europe- Respiratory products: $54 million compared to the $55.36 million average estimate based on three analysts. The reported number represents a change of +3.9% year over year.
• Geographic Revenue- International Markets- Generic products (including OTC and biosimilars): $407 million versus $433.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.3% change.
• Geographic Revenue- International Markets- COPAXONE: $8 million versus the three-analyst average estimate of $7.88 million. The reported number represents a year-over-year change of 0%.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Shares of Teva Pharmaceutical Industries have returned +2.6% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.